Immutep is a late-stage clinical biotechnology company developing novel LAG-3 immunotherapies to fight cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and harness its unique ability to stimulate or s...See more
Headquarter Australia |
Countries of operation Australia |
Funding status Publicly listed on stock exchange |
Company type MNC / Large Enterprise |
Chairman of the Board
Finance Director and Assistant Company Secretary
Senior Clinical Trial Manager
Share capital injection/new funding: approx. USD 59,700,000
Job title | Name | Email | Country based in | Job Function | Seniority | |
---|---|---|---|---|---|---|
Chairman of the Board | hidden.item | hidden.item | hidden.item | |||
Finance Director and Assistant Company Secretary | hidden.item | hidden.item | hidden.item | |||
Senior Clinical Trial Manager | hidden.item | hidden.item | hidden.item |